Preserved expression of mRNA coding von willebrand factor–cleaving protease ADAMTS13 by selenite and activated protein C

Molecular Medicine

Volumn 21, Issue , 2015, Pages 355-363

  Ekaney, Michael L ^a   Bockmeyer, Clemens L ^b   Sossdorf, Maik ^a   Reuken, Philipp A ^a   Conradi, Florian ^a   Schuerholz, Tobias ^b   Blaess, Markus F ^a   Friedman, Scott L ^c   Lösche, Wolfgang ^a   Bauer, Michael ^a   Claus, Ralf A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE DOMAIN CONTAINING PROTEIN 12; ADAM PROTEIN; ARGIPRESSIN; COLLAGEN; DESMOPRESSIN; DROTRECOGIN; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; SELENITE; TOLVAPTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; AUTACOID; CYTOKINE; MESSENGER RNA; PROTEIN C; SELENIOUS ACID; VON WILLEBRAND FACTOR;

ADAMTS13 GENE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SEPSIS; BLOOD; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; LIVER; METABOLISM;

ADAM PROTEINS; ADAMTS13 PROTEIN; CYTOKINES; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; LIVER; PROTEIN C; PROTEOLYSIS; RNA, MESSENGER; SELENIOUS ACID; SEPSIS; TRANSCRIPTION, GENETIC; VON WILLEBRAND FACTOR;

EID: 84938878133     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00202     Document Type: Article

References (70)

1. Angus DC, Pereira CA, Silva E. (2006) Epidemiology of severe sepsis around the world. Endocr. Metab. Immune Disord. Drug Targets 6:207-12.
2. Martin GS, Mannino DM, Eaton S, Moss M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-54.
3. Deutschman CS, Tracey KJ. (2014) Sepsis: current dogma and new perspectives. Immunity. 40:463-75.
4. Angus DC, van der Poll T. (2013) Severe sepsis and septic shock. N. Engl. J. Med. 369:840-51.
5. Bone RC, et al. (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 136:e28.
6. Aird WC. (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765-77.
7. Aird WC. (2007) Endothelium as a therapeutic target in sepsis. Curr. Drug Targets. 8:501-7.
8. Czabanka M, Peter C, Martin E, Walther A. (2007) Microcirculatory endothelial dysfunction during endotoxemia-insights into pathophysiology, pathologic mechanisms and clinical relevance. Curr. Vasc. Pharmacol. 5:266-75.
9. Bockmeyer CL, et al. (2008) Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematol. 93:137-140.
10. Kayal S, Jais JP, Aguini N, Chaudiere J, Labrousse J. (1998) Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am. J. Respir. Crit. Care Med. 157:776-84.
11. Ruggeri ZM. (2003) von Willebrand factor, platelets and endothelial cell interactions. J. Thromb. Haemost. 1:1335-42.
12. Arya M, et al. (2002) Ultralarge multimers of von Willebrand factor form spontaneous highstrength bonds with the platelet glycoprotein Ib- IX complex: studies using optical tweezers. Blood. 99:3971-7.
13. Andrews RK, Berndt MC. (2004) Platelet physiology and thrombosis. Thromb. Res. 114:447-53.
14. Uemura M, et al. (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood. 106:922-4.
15. Levy GG, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:488-94.
16. Zhou Z, Nguyen TC, Guchhait P, Dong JF. (2010) von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Sem. Thromb. Hemost. 36:71-81.
17. Symmers WS. (1952) Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br. Med. J. 2:897-903.
18. Wang Z, et al. (2010) Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome. Clin. Appl. Thromb. Hemost. 17:251-3.
19. Kinasewitz GT, Zein JG, Lee GL, Nazir SA, Taylor FB Jr. (2005) Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis. Crit. Care Med. 33:2214-21.
20. Chertow GM, et al. (2006) Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int. 70:1120-6.
21. Vincent JL, Yagushi A, Pradier O. (2002) Platelet function in sepsis. Crit. Care Med. 30:S313-7.
22. Vischer UM. (2006) von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J. Thromb. Haemost. 4:1186-93.
23. Kremer Hovinga JA, et al. (2007) ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J. Thromb. Haemost. 5:2284-90.
24. Larkin D, et al. (2009) Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog. 5:e1000349.
25. Peigne V, et al. (2013) The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit. Care. 17:R273.
26. Claus RA, Bockmeyer CL, Sossdorf M, Losche W. (2010) The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? Curr. Mol. Med. 10:236-48.
27. Nguyen TC, et al. (2008) Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia- associated multiple organ failure. Crit. Care Med. 36:2878-87.
28. Bockmeyer CL, et al. (2011) ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition. Thromb. Haemost. 105:145-53.
29. Ono T, et al. (2006) Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 107:528-34.
30. Claus RA, et al. (2009) Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb. Haemost. 101:239-47.
31. Mannucci PM, et al. (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 98:2730-5.
32. Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. (2008) Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J. Thromb. Haemost. 6:1233-5.
33. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. (2004) Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow. Blood. 104:100-6.
34. Crawley JT, et al. (2005) Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 105:1085-93.
35. Mimuro J, et al. (2008) Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxinemia. Thromb. Res. 122:91-7.
36. Lerolle N, et al. (2009) von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J. Thromb. Haemost. 7:843-50.
37. Xu L, et al. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 54:142-51.
38. Weiskirchen R, et al. (2013) Genetic characteristics of the human hepatic stellate cell line LX-2. PloS One. 8:e75692.
39. Ades EW, et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99:683-90.
40. Ceppi ED, Smith FS, Titheradge MA. (1996) Effect of multiple cytokines plus bacterial endotoxin on glucose and nitric oxide production by cultured hepatocytes. Biochem. J. 317(Pt 2):503-7.
41. Kuhn UD, Rost M, Muller D. (2001) Para-nitrophenol glucuronidation and sulfation in rat and human liver slices. Exp. Toxicol. Pathol. 53:81-7.
42. Pfaffl MW. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
43. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J. Haematol. 129:93-100.
44. Claus RA, Bockmeyer CL, Sossdorf M, Losche W, Hilberg T. (2006) Physical stress as a model to study variations in ADAMTS-13 activity, von Willebrand factor level and platelet activation. J. Thromb. Haemost. 4:902-5.
45. Reuken PA, et al. (2014) Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int. 35:37-45.
46. Bai X, et al. (2014) Early versus delayed administration of norepinephrine in patients with septic shock. Crit. Care. 18:532.
47. Pecori Giraldi F, et al. (2011) von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing’s disease. Br. J. Clin. Pharmacol. 71:132-6.
48. Dziaman T, et al. (2009) Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol. Biomarkers Prev. 18:2923-8.
49. Christiaans SC, Wagener BM, Esmon CT, Pittet JF. (2013) Protein C and acute inflammation: a clinical and biological perspective. Am. J. Physiol. Lung Cell. Mol. Physiol. 305:L455-66.
50. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. (2009) Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood. 114:5102-11.
51. Kume Y, et al. (2007) Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Lett. 581:1631-4.
52. Niiya M, et al. (2006) Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4:1063-70.
53. Grillberger R, et al. (2014) A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay. J. Thromb. Haemost. 12:1523-32.
54. Juul KV, Bichet DG, Nielsen S, Norgaard JP. (2014) The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am. J. Physiol. renal Physiol. 306:F931-40.
55. Reiter RA, Knobl P, Varadi K, Turecek PL. (2003) Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 101:946-8.
56. Reiter RA, Varadi K, Turecek PL, Jilma B, Knobl P. (2005) Changes in ADAMTS13 (von-Willebrand- factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb. Haemost. 93:554-8.
57. Shomron N, et al. (2010) A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thromb. Haemost 104:531-5.
58. Alkozai EM, et al. (2015) No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thromb. Res. 135:292-7.
59. Fukushima H, et al. (2013) Ratio of von Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis. Shock. 39:409-14.
60. Page AV, Liles WC. (2013) Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence. 4:507-16.
61. Yamaguchi M, et al. (2006) Decreased protein C activation in patients with fulminant hepatic failure. Scand J. Gastroenterol. 41:331-7.
62. Zhang F, et al. (2002) Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atheroscler. 161:381-6.
63. Tolando R, Jovanovic A, Brigelius-Flohe R, Ursini F, Maiorino M. (2000) Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effect of selenium supplementation. Free Radic. Biol. Med. 28:979-86.
64. Steinbrenner H, Bilgic E, Alili L, Sies H, Brenneisen P. (2006) Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic. Res. 40:936-43.
65. Chauhan AK, et al. (2008) ADAMTS13: a new link between thrombosis and inflammation. J. Exp. Med. 205:2065-74.
66. Heyland DK, Dhaliwal R, Suchner U, Berger MM. (2005) Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med. 31:327-37.
67. Sakr Y, et al. (2014) Adjuvant selenium supplementation in the form of sodium selenite in postoperative critically ill patients with severe sepsis. Crit. Care. 18:R68.
68. Forceville X. (2007) Effects of high doses of selenium, as sodium selenite, in septic shock patients a placebo-controlled, randomized, double-blind, multi-center phase II study-selenium and sepsis. J. Trace Elem. Med. Biol. 21 Suppl 1:62-5.
69. Bosse AC, et al. (2010) Impact of selenite and selenate on differentially expressed genes in rat liver examined by microarray analysis. Biosci. Rep. 30:293-306.
70. Dellinger RP, et al. (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41:580-637.